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| BACKG ROU N D
Waitlist mortality in children awaiting LT remains high, with rates of 12%-15% in patients <2 years of age. [1] [2] [3] To improve on this, it is critical for pediatric liver transplant centers to find alternate strategies to mitigate this risk of waitlist mortality by increasing donor availability and effective organ allocation. 4 Interest in ABO-ILT has recently been renewed for select patients to broaden the donor pool and result in timelier LT. 5, 6 There is evolving evidence that complications historically associated with this procedure such as biliary, vascular, and early graft failure can be minimized with improved treatment protocols based on immunological monitoring prior to LT. [7] [8] [9] [10] Although recent studies report improved outcomes with ABO-ILT in younger children, 6, [11] [12] [13] immunological monitoring prior to ABO-ILT is lacking and treatment protocols for pediatric deceased donor transplantation are not standardized.
IH are preformed IgM antibodies in circulation which can react to major blood group antigens A, B, and O on vascular endothelium in ABO-incompatible allografts. These antigen-antibody interactions can lead to complement activation, inflammation, and necrosis of the allograft resulting in early graft failure. 14 In LT, this can further cause vascular and biliary tract complications. 8 To combat these preformed antibodies, countries outside the United States, where more than 10% of all living donor LTs are ABO-incompatible, have incorporated desensitization protocols based on pretransplant IH using rituximab and plasma exchange with excellent post-transplant survival rates.
7,15-17
Such treatment protocols are not directly applicable to deceased donor pediatric ABO-ILT, however, due to the unpredictable timing of the transplant operation. Consequently, we developed and implemented a novel ABO-ILT management protocol for pediatric deceased donor LT based on pretransplant IH levels in a high volume center. The purpose of this protocol was to provide simplified and standardized evaluation, listing, and tailored management of pediatric ABO-ILT based on pretransplant IH titers. In addition, we compared post-transplant outcomes of deceased donor ABO-ILT patients to ABO-CLT during the same period at our institution.
| ME THODS

| Patient selection
We developed an ABO-ILT management protocol for deceased donor LT based on pretransplant IH titers. All ABO-ILT and ABO-CLT patients received intravenous methylprednisolone (20 mg/kg; maximum dose 1 g) intraoperatively at the time of anastomosis followed by prednisone taper. Patients in both the groups received oral tacrolimus within a day of LT using our standard twice-daily dosing regimen, adjusted by trough measurements to target 10-12 ng/mL in the initial weeks after LT.
Following LT, IH titers were monitored daily in the ABO-ILT group for the first week, weekly for 3 weeks, monthly for 3 months, and then with annual laboratories. Additional IH panels were sent if there was suspicion for possible allograft rejection. When required, children who underwent ABO-ILT received plasma and platelet products compatible to both recipient and donor blood types (Table S1 ).
| Data collection and study design
The institutional review board at Baylor College of Medicine ap- 
| Statistical analysis
We used STATA13 (StataCorp LP, College Station, TX, USA) for data analysis. A P-value of <0.05 was considered statistically significant for all analyses. We summarized demographics, clinical characteristics, and complications 1 and 3 years post-transplantation using frequency with percentage and median with 25th and 75th percentiles. We compared patient characteristics and post-transplant complications in ABO-CLT and ABO-ILT groups using Fisher's exact test or Wilcoxon rank sum test. Time to complications was compared between groups using log-rank test and presented using Kaplan-Meier curves. IH titers were graphed over time post-transplantation for ABO-ILT patients.
| RE SULTS
Ten children received an ABO-ILT over the 24-month study period, with a median age of 8.9 months (range 5.1 months to 9.3 years). All patients were under 24 months of age except for a 9-year-old patient with acute liver failure. Five patients (50%) were female. The most common indication for LT was BA (60%). Nineteen ABO-CLT recipients with similar age, indication for LT, and medical acuity who underwent LT during the same period were included in the comparison group. Patients in both groups were listed with a PELD score of greater than or equal to 30 reflecting high medical acuity. Patient characteristics for both the groups are comparable and shown in Table 1 .
| Pretransplant management
Three of ten ABO-ILT recipients had an initial IH titer against the donor blood type of ≥1:32. Peak pre-LT antibody titer in our cohort was 1:512 in an 8-month-old infant with BA (patient # 7). One additional child (patient #8) received enhanced IS protocol despite titer of 1:16 because she had received TPE pretransplantation due to uncontrolled coagulopathy. Although her titer at the time of transplant was below our cutoff, there was concern that it may not adequately reflect her humoral functional capacity due removal of circulating antibody by TPE with AB plasma prior to day of transplant. None of the patients in our group had TPE catheter-related complications.
Blood group types and IH titers for ABO-ILT group along with details of anastomosis are shown in Table 2 .
In our cohort of patients, age at transplant was not associated with the presence or absence of antibody to blood group antigens, as patients under 1 year of age had high IH titers pretransplantation (Spearman r = −.219, P = 0.6).
Median total wait time from listing to transplantation was 75.5 
| Changes in isohemagglutinin titers post-ABO-ILT
We monitored IH titers per protocol after transplant. Patient #10
had a rebound IH anti-B titer of 1:128 on week 2; however, immediate follow-up the next day was 1:64, and hence no alteration was made to the IS management. At a median of 2.8 years post-ABO-ILT, relevant IH titers remain <1:2 for all patients. Figure 2 shows the trend of IH titers pre-and post-ABO-ILT.
| Complications post-transplant
We compared between the patient groups rate of infections, acute rejection of allograft, biliary, and vascular complications in the first year after LT (Table 3 ) and in long-term follow-up with median time Figure 3B ).
There were no significant differences in the rate or severity of infection between the groups. We observed bacterial infections in 70% and viral infections in 50% in the ABO-ILT group, which was comparable to 64% and 57%, respectively, in the ABO-CLT group.
Gram-negative rods and adenovirus were the most commonly iso- in this large series, recipients <2 years of age at the time of LT had significantly better outcomes compared to recipients ≥2 (81.2% VS 50.2%). 22 Our study adds to the current limited literature in ABOincompatible deceased donor LT demonstrating good patient and graft survival similar to other pediatric analyses.
6,12,21
Small single-center studies in children undergoing living-related donor transplantation suggest elevation of IH titers after transplantation may be a predictive risk factor for increased mortality and morbidity and the reduction in titers of antidonor blood type antibodies using TPE and rituximab can achieve favorable outcomes. 7, 15, 23 Including rituximab is critical, in combination with ABO-ILT has been associated with increased rejection and infection rates in both adult and pediatric populations. The strength of our data is that the rate of allograft rejection post-LT was comparable in ABO-ILT group to the ABO-CLT group. This we attribute to our unique protocol, as we monitor IH titers pretransplant and alter IS selectively for patients with high IH titers in order to prevent the There are several limitations to this study. We tested for IgM antibodies, but additional testing of IgG antibodies to donor antigens may be important and the significance of such monitoring is currently unknown. Although our institution is a high volume pediatric LT center, we have limited sample size for the study especially in children older than 2 years of age who underwent ABO-ILT, limiting statistical power and analysis. An additional limitation is lack of longterm follow-up to evaluate graft outcomes in ABO-ILT group. We will continue to monitor IH titers annually and with any for-cause liver biopsies in these patients.
In conclusion, transplanting across blood group barriers can be successful in young patients, under the age of two with careful management, even with high pretransplant IH titers. Our experience adds evidence for this approach and suggests consideration of titerbased management of ABO-ILT in patients who otherwise might not receive a donor organ in a timely fashion on the LT waiting list.
Future multicenter studies and longer follow-up periods are necessary to routinely implement this IS protocol for ABO-ILT.
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